Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing. Fourth quarter GAAP gross margin of 71.7%, ...
RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc (IRD). (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results